Appreciate the drama — but I won’t be signing up for any Federal Court adventure just yet.
Yes, biotech is volatile. Yes, Chimeric has had its stumbles. That’s the nature of high-risk, high-reward sectors. But unlike the doom-and-gloom narrative, I actually think the company’s on track. So does the entity that just dropped a $4 million donation into it — presumably not for the fun of it.
I’ve averaged down, held my nerve, and I’m cautiously optimistic we’re emerging from the worst.
Thanks for the enthusiasm.
CHM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)